Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1

Conditions

Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1

Interventions

fludarabine phosphate 90Cyclophosphamide 85Mycophenolic Acid 67Peripheral Blood Stem Cell Transplantation 65Whole-Body Irradiation 59Tacrolimus 58Cyclosporine 46Busulfan 45Antilymphocyte Serum 39fludarabine 35Filgrastim 35Melphalan 33Methotrexate 28Radiotherapy 26Granulocyte Colony-Stimulating Factor 20Sirolimus 17Methylprednisolone 17Etoposide 17Cord Blood Stem Cell Transplantation 17Rituximab 14Stem Cell Transplantation 13Alemtuzumab 13thymoglobulin 11sargramostim 11Cyclosporins 11Therapeutics 10Flow Cytometry 10Cytarabine 10plerixafor 8Thiotepa 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hodgkin Disease × pegaspargase × Plasma cell × Clear all
NCT00837200 2017-07-24

Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies

Milton S. Hershey Medical Center

Phase 2 Terminated
13 enrolled 12 charts
LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡